News | July 18, 2022
India crosses ‘200 Crore’ COVID-19 vaccinations
PM congratulates citizens on crossing the 200 crore milestone of Covid vaccination drive
PM congratulates citizens on crossing the 200 crore milestone of Covid vaccination drive
Novavax' vaccine is the first protein-based COVID-19 vaccine authorized in the U.S.
Proportion of the eligible population yet to receive a COVID-19 vaccine is comparatively small
The vaccine is under FDA review
105 million 30 µg, 10 µg and 3 µg doses to be delivered into Q4 2022, with an option for the U.S. Government to purchase up to 195 million additional doses
States were also strongly advised to strictly monitor epidemiological profile of admitted COVID patients
Both vaccine candidates demonstrated a favorable safety and tolerability profile similar to the Pfizer-BioNTech COVID-19 Vaccine
The Minister directed officials to continue to focus on surveillance and on Whole Genome Sequencing to scan for any possible mutation and also directed for monitoring hospitalizations due to COVID-19 and SARI/ILI cases
An interim analysis of this data shows no significant safety issues and a 91% seroconversion rate at Day 56.
COR803 is a novel small molecule 3CLpro inhibitor discovered and developed by Cortexyme based on its expertise in cysteine protease inhibition.
Subscribe To Our Newsletter & Stay Updated
